Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer

Background/Objectives: Adding docetaxel to androgen deprivation therapy (ADT) prolongs survival in metastatic prostate cancer, but not all patients benefit, and no early biomarker identifies individuals with resistant disease. We assessed whether serial circulating tumour cell (CTC) sampling adds prognostic information beyond a pre-treatment sample. Methods: CTCs were enriched by size and deformability (Parsortix®) and phenotyped as epithelial (CK+/VIM−/CD45−), mesenchymal (CK−/VIM+/CD45−), or EMTing (CK+/VIM+/CD45−) at four time points in 61 patients treated with ADT and docetaxel (43 hormone-sensitive; 18 resistant, exploratory). Results: With longer follow-up, our previously reported baseline CTC predictors remained associated with overall survival (OS). In hormone-sensitive patients, baseline ≥ 6 total (HR 3.21, p = 0.007) and epithelial CTCs (p = 0.017) were associated with shorter OS. Across baseline, early, and late treatment, the OS hazard ratio for epithelial CTCs fell (2.59, 2.29, 2.11), yet for ≥3 mesenchymal CTCs rose (1.99, 2.99, 4.08). No single time point result survived false-discovery-rate correction. During early treatment, radiographic responders had fewer mesenchymal CTCs than non-responders (median 0 vs. 2.5, p = 0.032), whereas PSA did not differ (p = 0.642). Persistence of ≥3 mesenchymal CTCs from baseline to late treatment identified the poorest outcome (n = 3; median OS 17.3 months vs. not reached) and survived false-discovery-rate correction (q = 0.019). Late treatment mesenchymal CTCs added value to baseline PSA (p = 0.024) and ALP (p = 0.019) and added potential value to the best baseline marker (≥6 CTCs, p = 0.125), identifying some high-risk patients with baseline < 6 CTCs. Conclusions: Early on-treatment CTC samples may help predict response, while late treatment mesenchymal CTCs may add to baseline clinical markers. These hypothesis-generating findings require validation in a larger prospective cohort.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-17
DOI
https://doi.org/10.3390/cancers18223671
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer

Myria Galazi, Glenda Scandura, Prabhakar Rajan, Oleg B. Blyuss et al.
1 links
Cancers
Prostate Cancer Treatment and Research
article

Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer

Myria Galazi, Glenda Scandura, Prabhakar Rajan, Oleg B. Blyuss, Jonathan Shamash, Greg L. Shaw, Constantine Alifrangis, Shanthini Mary Crusz, Karen Tipples, Edwina Burke, Alistair Grey, Yong‐Jie Lu, Elzbieta Stankiewicz, Daniel Maurice Berney, Akhila Ganeshi Wimalasingham, Caitlin R. Davies, Thomas B. Powles, Sakunthala C. Kudahetti, Xueying Mao, Lei Xu, Sarah McCarley, Tianyu Guo
article en

Abstract

Background/Objectives: Adding docetaxel to androgen deprivation therapy (ADT) prolongs survival in metastatic prostate cancer, but not all patients benefit, and no early biomarker identifies individuals with resistant disease. We assessed whether serial circulating tumour cell (CTC) sampling adds prognostic information beyond a pre-treatment sample. Methods: CTCs were enriched by size and deformability (Parsortix®) and phenotyped as epithelial (CK+/VIM−/CD45−), mesenchymal (CK−/VIM+/CD45−), or EMTing (CK+/VIM+/CD45−) at four time points in 61 patients treated with ADT and docetaxel (43 hormone-sensitive; 18 resistant, exploratory). Results: With longer follow-up, our previously reported baseline CTC predictors remained associated with overall survival (OS). In hormone-sensitive patients, baseline ≥ 6 total (HR 3.21, p = 0.007) and epithelial CTCs (p = 0.017) were associated with shorter OS. Across baseline, early, and late treatment, the OS hazard ratio for epithelial CTCs fell (2.59, 2.29, 2.11), yet for ≥3 mesenchymal CTCs rose (1.99, 2.99, 4.08). No single time point result survived false-discovery-rate correction. During early treatment, radiographic responders had fewer mesenchymal CTCs than non-responders (median 0 vs. 2.5, p = 0.032), whereas PSA did not differ (p = 0.642). Persistence of ≥3 mesenchymal CTCs from baseline to late treatment identified the poorest outcome (n = 3; median OS 17.3 months vs. not reached) and survived false-discovery-rate correction (q = 0.019). Late treatment mesenchymal CTCs added value to baseline PSA (p = 0.024) and ALP (p = 0.019) and added potential value to the best baseline marker (≥6 CTCs, p = 0.125), identifying some high-risk patients with baseline < 6 CTCs. Conclusions: Early on-treatment CTC samples may help predict response, while late treatment mesenchymal CTCs may add to baseline clinical markers. These hypothesis-generating findings require validation in a larger prospective cohort.

CancersVol. 18(22)
University College Hospital (GB), University College London Hospitals NHS Foundation Trust (GB), Institute of Cancer Research (GB), Queen Mary University of London (GB), Barts Health NHS Trust (GB), Fudan University (CN), Zhongshan Hospital (CN), Barts Cancer Institute (GB), University College London (GB), Gdańsk Medical University (PL)
Cancer Research UK
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon